Non-Fucosylated Anti-Human LRP6 (YW210.09) Therapeutic Antibody (CAT#: BioBet-1188ZP) Datasheet

LRP6

low density lipoprotein receptor-related protein 6

This gene encodes a member of the low density lipoprotein (LDL) receptor gene family. LDL receptors are transmembrane cell surface proteins involved in receptor-mediated endocytosis of lipoprotein and protein ligands. The protein encoded by this gene functions as a receptor or, with Frizzled, a co-receptor for Wnt and thereby transmits the canonical Wnt/beta-catenin signaling cascade. Through its interaction with the Wnt/beta-catenin signaling cascade this gene plays a role in the regulation of cell differentiation, proliferation, and migration and the development of many cancer types. This protein undergoes gamma-secretase dependent RIP- (regulated intramembrane proteolysis) processing but the precise locations of the cleavage sites have not been determined.

LRP6; low density lipoprotein receptor-related protein 6; ADCAD2; low-density lipoprotein receptor-related protein 6; LRP-6

Plasma membrane, Endoplasmic reticulum

Diseases associated with LRP6 include Coronary Artery Disease, Autosomal Dominant 2 and Tooth Agenesis, Selective, 7.

Its related pathways are Signaling by GPCR and S45 mutants of beta-catenin arent phosphorylated.

The components of wnt-fzd-lrp5-lrp6 complex trigger the - Catenin signal by inducing the receptor ligand complex to aggregate into ribosome sized signal bodies. Wnt / - catenin signaling on the cell surface CO receptor plays a key role in bone formation. Wnt induced Fzd / LRP6 co receptor complex recruits DVL1 polymer to plasma membrane, and then recruits AXIN1 / gsk3b complex to cell surface to promote the formation of signal bodies and inhibit AXIN1 / GSK3 mediated phosphorylation and - Catenin destruction. The post model of the ectoderm (due to similarity) is necessary during gastrulation.

Cell Biology and Cellular Response antibody; Developmental Biology antibody; Metabolism antibody; Neuroscience antibody; Signaling Transduction antibody

Dual phosphorylation of cytoplasmic PPPSP motifs sequentially by GSK3 and CK1 is required for AXIN1-binding, and subsequent stabilization and activation of beta-catenin via preventing GSK3-mediated phosphorylation of beta-catenin. Phosphorylated, in vitro, by GRK5/6 within and outside the PPPSP motifs. Phosphorylation at Ser-1490 by CDK14 during G2/M phase leads to regulation of the Wnt signaling pathway during the cell cycle. Phosphorylation by GSK3B is induced by RPSO1 binding and inhibited by DKK1. Phosphorylated, in vitro, by casein kinase I on Thr-1479. Undergoes gamma-secretase-dependent regulated intramembrane proteolysis (RIP). The extracellular domain is first released by shedding, and then, through the action of gamma-secretase, the intracellular domain (ICD) is released into the cytoplasm where it is free to bind to GSK3B and to activate canonical Wnt signaling. Palmitoylation on the two sites near the transmembrane domain leads to release of LRP6 from the endoplasmic reticulum. Mono-ubiquitinated which retains LRP6 in the endoplasmic reticulum. Ubiquitinated by ZNRF3, leading to its degradation by the proteasome. N-glycosylation is required for cell surface location.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

YW210.09

Humanized

Human

The anti-LRP6 antibody are used for the treatment of cancer or skeletal disorders.

Cancer; Skeletal Disorders

Cancer; Skeletal Disorders